Inside Wall Street: Newly Independent Mead Johnson Could Be Buyout Bait

Mead Johnson (MJN) is getting a lot of fresh attention on Wall Street. Now an independent publicly traded company after Bristol-Myers Squibb (BMY) sold its controlling 83% stake in December, Mead is attracting new interest not just because of its global dominance in infant formula and children's nutritional products. It's also a potential buyout target.